Please assess the completion status of the following clinical trial:

Trial Title: (CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Able to perform reproducible spirometry according to American Thoracic Society (ATS) criteria~* History of asthma symptoms that are adequately controlled in the 4 weeks prior to study entry, and meets at least one of the following criteria:~  1. History of mild persistent asthma symptoms (on average greater than 2 days per week with symptoms or albuterol use for symptoms or greater than 2 night-time awakenings per month during the year prior to study entry) and has been treated with a single-controller inhaled corticosteroid (ICS) dose less than or equal to 160 mcg per day of a beclomethasone-equivalent or a leukotriene receptor antagonist (LTRA) (in an age-appropriate dose) for the 4 weeks prior to study entry; individuals treated with a combination controller therapy (e.g. ICS+LTRA or ICS+long-acting beta-agonist (LABA)) in the past 8 weeks will not be eligible~ 2. Not currently being treated with ICS, a history of mild persistent asthma, and 1 to 2 exacerbations in the year prior to study entry (but none in the 3 months prior to study entry)~* Forced expiratory volume in one second (FEV1) reversibility of greater than or equal to 12% following bronchodilator administration (4 puffs); individuals who do not meet this requirement may qualify for enrollment if their methacholine provocative concentration at 20% (PC20) is less than or equal to 12.5 milligrams per milliliter (mg/ml)~* History of clinical varicella or varicella vaccine; individuals needing the vaccine may receive it from their primary care physician prior to study entry~* Ability of parent to provide informed consent; verbal assent must be obtained from children less than 7 years of age and written assent must be obtained from children between 7 and 18 years of age~* If female, willing to use an effective form of contraception~Participants will be eligible for the 44 weeks of treatment if, after the 4-week screening period, their asthma remains controlled, and they demonstrate at least 80% predicted pre-bronchodilator FEV1. Participants must meet ALL of the criteria stated below during the 8-week screening period to continue in the study:~* Meets the definition of acceptable asthma control, which is NOT having one or more of the following during ANY 2-week period:~  1. On average, on more than 2 days per week, experiences one or more of the following:~     1. Diary-reported symptoms~    2. The use of inhaled bronchodilator (not including pre-exercise)~    3. Peak flows in the yellow zone (less than 80% of personal best defined as based on peak expiratory flow (PEF) value obtained at study visit 1~ 2. More than 1 night-time awakening due to asthma~* Demonstrates adherence with taking study medications (at least 75% of scheduled doses), rescue medications (using both rescue inhalers for at least 75% of rescue doses), and completing patient diaries (at least 75% of days)~* Pre-bronchodilator FEV1 greater than or equal to 80% predicted at study visits 2 and 3~* Agrees to not use a spacer with beclomethasone/placebo study and rescue medications~NOTE: In January 2008, the Data and Safety Monitoring Board (DSMB) approved changes in the TREXA eligibility criteria, by which neither FEV1 reversibility ≥ 12% nor a participant's methacholine PC20 ≤ 12.5 mg/ml were required for randomization.~Exclusion Criteria:~* Corticosteroid treatment for any condition prior to study entry within the following defined timepoints:~  1. Oral - Use within 2-week period of the screening visit~ 2. Injectable - Use within 2-week period of the screening visit~ 3. Nasal corticosteroids may be used at any time during the study at the discretion of the study investigator or primary care physician~* Current or prior use of medications known to significantly interact with corticosteroid disposition (within a 2-week period of study visit 1), including but not limited to carbamazepine, erythromycin or other macrolide antibiotics, phenobarbital, phenytoin, rifampin, or ketoconazole~* Pre-bronchodilator FEV1 less than 60% predicted at study visit 1~* Any hospitalization for asthma in the year prior to study entry~* Presence of chronic or active lung disease other than asthma~* Significant medical illness other than asthma, including thyroid disease, diabetes mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent medical problems that could require oral corticosteroids during the study~* History of cataracts, glaucoma, or any other medical disorder associated with an adverse effect to corticosteroids~* Any asthma exacerbation in the past 3 months or more than 2 in the past year.~* History of a life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure~* History of adverse reactions to ICS preparations or any of its ingredients~* Receiving hyposensitization therapy other than an established maintenance regimen (continuous regimen for at least 3 months)~* Pregnant or breastfeeding~* Cigarette smoking or smokeless tobacco use in the year prior to study entry~* Refusal to consent to a genotype evaluation~* Current participation or participation within 1 month of study entry in another investigational drug trial~* Evidence that the family may be unreliable or nonadherent, or may move from the clinical center area before study completion

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Daily ICS + Rescue ICS (Type: EXPERIMENTAL): Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir®™ 90 mcg Inhalation Aerosol) rescue puffs as needed
- Daily ICS (Type: ACTIVE_COMPARATOR): Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
- Rescue ICS (Type: EXPERIMENTAL): Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
- Placebo (Type: PLACEBO_COMPARATOR): Albuterol sulfate administered via a hydrofluoroalkane (HFA) inhaler (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete